People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RheumaGen, Inc. | — | Biotechnology | Series A | $7.9M | $4.1M | 2022 |
Ryan Kane Hart at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ryan Kane Hart on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brian M. Freed | 1 | 2 |
| James Brian Hart, Jr. | 1 | 1 |
| Bobak Robert Mozayeni | 1 | 1 |
| Thomas Matthew Fratacci | 1 | 1 |
| Brian Matthew Freed | 1 | 1 |
| Richard Anthony Freed, III | 1 | 1 |
| Bruce Michael Goodwin | 1 | 1 |
| Gregory L. Andrews | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.